Research programme: neurological disorders therapies - Allergan/Syntaxin

Drug Profile

Research programme: neurological disorders therapies - Allergan/Syntaxin

Alternative Names: SXN 113

Latest Information Update: 17 Jul 2015

Price : $50

At a glance

  • Originator Health Protection Agency
  • Developer Syntaxin
  • Class Analgesics; Botulinum toxins; Recombinant proteins
  • Mechanism of Action SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 23 Jul 2013 No development reported - Preclinical for Neurological disorders in United Kingdom (unspecified route)
  • 23 Jul 2013 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
  • 15 Jul 2013 Ipsen acquires Syntaxin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top